Plain Language Summary {#S0001}
======================

Obesity is a multifactorial disease that includes both genetic and environmental factors and varies among individuals. Thus, the response to weight-loss programs is greatly influenced by individual differences and is not well understood. The fat mass and obesity-related (*FTO*) gene was the first gene found to be associated with body fat and obesity. Promoting *FTO* causes DNA decreased methylation, which leads to increased fat mass due to overeating. Conversely, increased DNA represses the *FTO* gene. However, the effects of weight-loss intervention programs on obesity in *FTO* DNA methylation and the relationship between body composition, metabolic index and physical fitness index are unknown. As a new index for assessing weight loss, we extracted DNA from blood to quantify *FTO* methylation and investigated the relationship between body composition and physical parameters. Eighteen women who completed a 6-month weight-loss program at the Obesity Outpatient Center at the Kansai Medical University Hospital Health Sciences Center were randomly divided into two groups: a normal treatment group (NTG) and a resistance training + treatment group (RTG). Only RTG increased the methylation rate of cytosine guanine dinucleotide 3 site (CpG3 site). Furthermore, there was a significant association between a decrease in the visceral fat area change rate and an increase in the CpG3 site methylation change rate. Therefore, the 6-month weight-loss program including resistance training may be associated with a decrease in visceral fat area change rate and an increase in CpG3 methylation change rate.

Introduction {#S0002}
============

The number of cases of type 2 diabetes (T2D), an obesity-related disease, is expected to increase to 593 million by 2035, and thus the increase in the proportion of people with obesity worldwide represents a global health problem.[@CIT0001] Health disorders caused by obesity range from T2D, dyslipidemia, hypertension, and hyperuricemia to coronary artery disease, cerebral infarction, sleep apnea syndrome, osteoarthritis, and kidney disease.[@CIT0002],[@CIT0003] Elimination/prevention of obesity is vital for reducing the incidence of such lifestyle-related diseases, for which dietary intervention and exercise therapy have been reported.[@CIT0004]--[@CIT0006] However, the response to weight-loss programs is greatly affected by individual differences, which are not well-understood.

In 2007, the fat mass and obesity-associated (*FTO*) gene, a genetic factor indicative of the susceptibility to obesity, was identified.[@CIT0007] *FTO* is associated with overeating, body fat mass, and obesity, with the strongest correlation observed with body mass index (BMI).[@CIT0008],[@CIT0009] Polymorphic risk allele homozygotes have been shown to have a 1.67-fold higher risk of developing obesity than those without these alleles.[@CIT0010] Studies also showed that physical activity can reduce the genetic risk of obesity by 30--40%.[@CIT0011],[@CIT0012] However, genetic polymorphisms are not thought to play an important role in obesity.[@CIT0013]

Obesity is a multifactorial disease involving both genetic and environmental factors which vary between individuals.[@CIT0014] As a molecular mechanism that mediates the interactions of these factors, studies have focused on epigenetics as the gene expression control mechanism.[@CIT0015]--[@CIT0017] Epigenetics regulates gene function without affecting the genomic sequence. This reversible phenomenon is controlled primarily by DNA methylation, histone modifications, and miRNAs.[@CIT0018] The most prominent feature of epigenetics is that it is affected by environmental factors and can be modified by intervention.[@CIT0019] Typically, increased methylation suppresses gene expression, whereas decreased methylation promotes gene expression.[@CIT0015]--[@CIT0020] Epigenetics is also tissue-specific; tissue types associated with obesity-related gene expression include the hypothalamus, liver, and adipose tissue.[@CIT0021],[@CIT0022] However, in the case of *FTO*, it is difficult to obtain DNA from the arcuate nucleus of the pituitary gland, which shows the highest expression level of this gene. There are a few reports of subcutaneous fat biopsies,[@CIT0023] but adipose tissue shows a high degree of cell-type heterogeneity, and changes in cell composition during weight loss can affect DNA methylation levels.[@CIT0024] However, it was recently verified that DNA methylation can be analyzed in the blood rather than in tissues.[@CIT0022],[@CIT0024]--[@CIT0028] Thus, DNA was extracted and analyzed from the blood, which is easily accessible, to evaluate the clinical situation of participants before and after an intervention treatment for obesity. We extracted DNA from blood samples and analyzed CpG at the nucleotide sequence position five prime untranslated region (5ʹUTR) (53704013--53704036) downstream of the promoter region of the *FTO* gene on chromosome 16.

The purpose of this study was to quantify *FTO* whole blood DNA methylation and to investigate its relationship with Body composition, Exercise capacity, and Blood parameters of a 6-month weight-loss program intervention.

Participants and Methods {#S0003}
========================

Study Participants {#S0003-S2001}
------------------

A total of 112 obese individuals attending the outpatient department at the Health Science Center of Kansai Medical University Hospital from March 2017 to October 2018 were included in the study. Individuals who consumed antidiabetic drugs or had secondary obesity, heart disease, cerebrovascular disease, other uncontrolled metabolic diseases, and orthopedic diseases that did not allow for exercise were excluded from the study. Women with a BMI of ≥25 kg/m^2^ were selected after providing written informed consent for participation in the study and were evaluated by a doctor for exercise. Subjects were randomized to the NTG or RTG at the first visit. This study was conducted with the approval of the Kansai Medical University Ethics Committee (approval number: 2016708).

NTG and RTG Program {#S0003-S2002}
-------------------

Subjects in the NTG exercised twice per month under the supervision of an exercise leader for six months. These activities consisted of 30 min of aerobic exercise (bicycle ergometer or treadmill) and full-body stretching.[@CIT0029],[@CIT0030] In addition, subjects exercised at home at the same level as in the supervised program, aiming for three sessions per week (150--180 min/week). Once per month, nutritionists provided education on dietary behavior, and psychologists provided counseling on cognitive behavioral therapy based on self-monitoring and self-efficacy.[@CIT0031]

In RTG, the normal training program included additional weight-bearing RT. Additional RTs were typically performed on the trunk and limb muscle groups (calf, squat, leg lift, trunk curl, knee lift, backcross, front bridge, back bridge, and twist). The protocol consisted of 2--4 events per day and 10--15 repetitions for two sets, with the exercises changed every month. The exercise frequency was more than 5 days per week, and exercise intensity was set at 11--13 using the Borg scale. The break between the event and the set was 30s. Once per month, the instructor provided individual guidance and ran the program at home. The exercise was recorded in the Weight Loss Achievement File, and guidance was provided on added or changed events after the instructor reviewed the rate of implementation during individual guidance. The "weight loss achievement file" provided to the subjects consisted of a description of the effects of weight-bearing RT, daily exercise program, and achievement record.

Body Composition {#S0003-S2003}
----------------

The height was measured in 0.1mm units using a height gauge, and the body weight was measured in 0.1g units using a body fat measuring device (DC-430A pole type, Nippon Tanita, Tokyo, Japan). The formula used to calculate BMI was weight (kg)/\[height (m)\]^2^. Body composition was determined using dual energy X-ray absorption (DPX-NT, GE Healthcare, Buckinghamshire, UK) and analyzed for fat mass (ratio), lean body mass, and skeletal muscle mass. Computed tomography (CT; GE Healthcare) and fat scan analysis software (East Japan Technology Tokyo Laboratory, Tokyo, Japan) for umbilical level visceral fat area (VFA) and subcutaneous fat area (SFA) were calculated. The measurements were taken during the first visit and at the 6-month post-intervention visit.[@CIT0031]

Calorie Intake {#S0003-S2004}
--------------

In the dietary survey, a nutritionist calculated the caloric intake of staple foods, caloric intake of snacks, and total caloric intake by the one-week recall method. The survey was conducted at the time of the first visit and at the time of the visit after 6 months of intervention.[@CIT0031]

Lower Limb Muscle Strength {#S0003-S2005}
--------------------------

Lower extremity muscle strength was measured twice using Strength Ergo (Mitsubishi Electric Corporation, Tokyo, Japan), based on uniform rotating leg strength. The maximum value was recorded and the weight (Nm/kg) correction value was used. The measurements were taken at the first visit and at the 6-month post-intervention visit.[@CIT0031]

Cardiopulmonary Exercise Test {#S0003-S2006}
-----------------------------

A cardiopulmonary exercise test (232C-XL; Combi Inc., Tokyo, Japan) was conducted to determine exercise tolerance. Scoring included 4 points of rest, 4 minutes of warm-up, and approximately 10 minutes of running under ramp load. Respiratory gas analysis was performed using the AE-300 system (Minato Medical Science, Osaka, Japan). Anaerobic threshold (AT) was determined using the V-gradient method. Peak maximum oxygen uptake (VO~2~) was defined as the maximum load at which AT and VO~2~ were recorded. The measurements were taken at the first visit and at the 6-month post-intervention visit.[@CIT0031]

Hematological Parameters {#S0003-S2007}
------------------------

Blood samples were obtained from the anterior cubital vein early morning prior to any food or drink consumption. Following centrifugation (at 25° C, 3000 rpm for 5 minutes), LDL-C (mmol/L) was measured using surfactant-based homogeneous assay, while HDL-C (mmol/L) was measured using peroxidase method, and TG (mmol/L) was measured using glycerol-3-phosphate oxidase (GPO) and peroxidase (POD) methods.

Plasma glucose (whole blood measurement) was measured by an amperometry method (Fully automatic glucose measuring device GA1170, GA1172, Arkray Japan) using a GOD-immobilized enzyme membrane and a hydrogen peroxide electrode. The homeostatic model assessment of insulin resistance (HOMA-IR) was used as an indicator of insulin resistance and was derived from fasting blood insulin (immunoreactive insulin) levels and early morning fasting blood glucose levels. The formula used was HOMA-IR = (immunoreactive insulin x fasting blood glucose)/405.[@CIT0031] Genomic DNA was extracted from whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to manufacturer's instructions. Blood was taken before and after the intervention.[@CIT0025],[@CIT0026]

DNA Methylation Using Pyrosequencing {#S0003-S2008}
------------------------------------

All target samples were analyzed before and after PyroSequence (PyroMark Q24 D; Qiagen) intervention.[@CIT0025],[@CIT0026],[@CIT0032]-[@CIT0035] PCR and sequencing primers were designed using PyroMark Assay Design 2.0 software (Qiagen), according to the recommended protocols. The primer sequences were designed by the primer design program "PSQ Assay" (Biotage, Uppsala, Sweden), using the gene sequences obtained from the NCBI GenBank entry. The primers were designed using a five prime untranslated region (5ʹUTR) near the transcription start site of the gene and in a region without single nucleotide polymorphisms downstream of the promoter region.[@CIT0025],[@CIT0026],[@CIT0036] The *FTO* primers were designed on chromosome 16: 53704013--53704036. [Table 1](#T0001){ref-type="table"} shows the primer information and a summary of specific CpG positions. Bisulfite conversion of 200 ng of genomic DNA was performed using the EpiTect kit (Qiagen). The bisulfite-converted DNA was amplified by polymerase chain reaction (PCR) using the PyroMark^®^ PCR Master Mix Kit (Qiagen) with a reverse primer biotinylated at the 5ʹend. Biotinylated PCR products were immobilized on streptavidin-coated beads (GE Healthcare) and DNA strands were separated using denaturing buffer. After washing and neutralizing on a PyroMark Q24 vacuum workstation, the PyroMark Q24 system (Qiagen) was used to analyze the sequencing primers for high-quantity bisulfite pyrosequencing. Using the Genome Reference Consortium Human Build 38/hg38, we identified a CpG at the nucleotide sequence position 5ʹUTR (53704013--53704036) downstream of the promoter region of the *FTO* gene on chromosome 16.Table 1Primer and *FTO* InfomationPrimerCpG CoveragePosition of CpG LociDistance from TSSF: 5ʹ-AGGAGTAAGGGAGAAATATGGTAGG-3'7Chr16; 53,704,013;+26R: 5ʹ-Biotin-CTCCCCTCTAAAACTATTCTCCCTCTAAA-3'Chr16; 53,704,018;+31S: 5ʹ-TGGGAAATTTTTTTGTGTTAA-3'Chr16; 53,704,022;+35Chr16; 53,704,024;+37Chr16; 53,704,031;+44Chr16; 53,704,034;+47Chr16; 53,704,036;+49[^1]

Statistical Analysis {#S0003-S2009}
--------------------

Clinical data were expressed as mean ± standard deviation or median (25--75% quartile). Normality was confirmed using the Shapiro--Wilk test. Parametric tests (paired *t*-test, independent sample *t*-test, Pearson's correlation coefficient) were used for the values showing the normal distribution. Nonparametric tests (Wilcoxon signed rank test, Mann Whitney *U*-test, Spearman rank correlation coefficient) were used for non-normal numbers. The methylation change rate (%CpG) was calculated from the data before and after the intervention ([Table 2](#T0002){ref-type="table"}). In stepwise multiple regression analysis, the methylation change rate (%CpG) that was significant before and after the inter-group intervention was the dependent variable, and a factor having a significant correlation with each methylation change rate (%CpG) was used as an independent variable, while age and the presence or absence of resistance training were analyzed as adjustment factors ([Table 3](#T0003){ref-type="table"}, [Table 4](#T0004){ref-type="table"}). The statistical software used was SPSS Statistics Grad Pack ver 26 for Windows (SPSS, Inc. Chicago, Illinois, USA) and the significance level was set to less than 5%.Table 2Methylation Rate and Methylation Change Rate of the *FTO* 5ʹ UTR RegionCpG LociNTG (n=9)RTG (n=9)Baseline ComparisonChange Rate ComparisonPrePostChange Ratep valuePrePostChange Ratep valuep valuep valueCpG1 (Chr16: 53,704,013)(%)3.0 (2.5, 3.1)2.3 (2.2, 2.4)^a^−18.3(−24.3,-11.4)^b^0.0112.3 (2.1, 2.9)2.3 (2.0, 3.1)17.2(−11.2,25.2)0.2140.0520.004CpG2 (Chr16: 53,704,018)(%)1.8 (1.3, 2.1)1.2 (1.1, 1.4)−20.3(−35.0, 22.9)0.3741.4 (1.2, 1.7)1.5 (1.1, 1.7)4.3(−31.4,34.6)0.7670.2700.566CpG3 (Chr16: 53,704,022)(%)1.8 (1.7, 2.2)1.7 (1.4, 2.1)−6.5(−26.2, 21.8)0.5942.0 (1.3, 2.1)2.2 (1.8, 2.7) ^a^28.4(−0.1,50.8)^a^0.0380.3100.038CpG4 (Chr16: 53,704,024)(%)0.7 (0.0, 0.8)0.0 (0.0, 0.6)^a^−100.0(−100.0,-8.44)0.0500.0 (0.0, 0.8)0.0 (0.0, 0.8)−100.0(0.0,0.0)0.6000.2750.127CpG5 (Chr16: 53,704,031)(%)1.6 (1.5, 1.7)1.4 (1.4, 1.6)^a^−12.1 (−23.8,-1.8)0.0211.8 (1.6, 1.9)1.5 (1.4, 1.8)−13.4(−22.0,-1.6)0.1230.6590.895CpG6 (Chr16: 53,704,034)(%)1.8 (1.5, 2.0)1.8 (1.6, 2.5)0.5(−12.4, 12.8)0.9531.8 (1.4, 2.2)1.6 (1.5, 1.8)−22.2(−32.9,20.2)0.1730.8250.331CpG7 (Chr16: 53,704,036)(%)0.9 (0.6, 0.9)0.0 (0.0, 0.9)^a^−45.5(−100.0,-4.65)0.0170.9 (0.4, 1.0)0.8 (0.0, 1.0)−61.1(−1.0,3.3)0.2370.7570.162Total value of CpG(%)11.0 (10.7, 12.0)9.6 (8.5, 10.2)^a^−20.7(−27.2,-10.1)^a^0.01110.3 (9.3, 11.5)9.8 (9.0, 11.2)−3.4(−8.1,4.5)0.5150.0580.019[^2] Table 3Correlation Between Methylation Change Rate and Various ParametersNTG (n=9)RTG (n=9)r*ρ*r*ρ***%CpG1** %Body weight−0.2670.4880.5830.099 %Body mass index−0.2670.4880.5830.099 %Body fat−0.683^a^0.0420.300^a^0.047 %Visceral fat area−0.6190.1020.3330.381 %Subcutaneous fat area−0.5950.1200.1170.765 %Total calorie intake−0.2500.5160.967^b^0.000 %Leg strength weight ratio0.6500.0580.1170.765 %AT0.3570.432−0.0330.932 %Peak VO~2~0.5950.120−0.3330.381 %HDL-C0.4670.2050.3830.308 %LDL-C−0.2330.5460.1670.668 %HOMA-IR0.1670.6680.1170.765 %HbA1c−0.1700.663−0.2430.529**%CpG3** %Body weight−0.0830.831−0.4670.205 %Body mass index−0.0830.831−0.4670.205 %Body fat−0.4170.265−0.5500.125 %Visceral fat area−0.5480.160−0.817^b^0.007 %Subcutaneous fat area−0.4760.233−0.3670.332 %Total calorie intake−0.2830.460−0.0170.966 %Leg strength weight ratio0.4670.205−0.0330.932 %AT−0.2860.5350.783^a^0.013 %Peak VO~2~0.2380.5700.1830.637 %HDL-C0.2670.4880.3830.308 %LDL-C0.2500.516−0.867^b^0.002 %HOMA-IR0.1000.798−0.1670.668 %HbA1c0.0510.897−0.2090.589**%Total value of CpG** %Body weight−0.5670.112−0.3670.332 %Body mass index−0.5670.112−0.3670.332 %Body fat−0.6330.0670.0670.865 %Visceral fat area−0.3810.3520.2670.488 %Subcutaneous fat area−0.2140.6100.2830.460 %Total calorie intake0.3830.308−0.1000.798 %Leg strength weight ratio0.3330.3810.2830.460 %AT−0.2500.5890.2830.460 %Peak VO~2~0.5950.1200.750^a^0.020 %HDL-C0.1830.637−0.0330.932 %LDL-C0.5000.1700.3830.308 %HOMA-IR0.1500.700−0.4170.265 %HbA1c−0.4580.2150.5770.104[^3] Table 4Independent Factors of %cpg1, %cpg3, and %Total Value of CpG Using Stepwise Multiple Regression AnalysisβpR^2^**%CpG1** Group0.592^b^0.0010.619 Age0.0880.584 %Body fat−0.0220.892 %Total calorie intake0.480^b^0.006**%CpG3** Group0.517^a^0.0120.527 Age−0.2800.134 %Visceral fat area−0.568^b^0.007 %AT0.1830.348 %LDL-C−0.3570.078**%Total value of CpG** Group0.401^a^0.0280.585 Age0.0060.972 %Peak VO~2~0.620^b^0.002[^4]

Results {#S0004}
=======

Adherence to the Exercise Training Program {#S0004-S2001}
------------------------------------------

Out of the 31 participant enrolled in this study, 13 had dropped out of the 6-month weight-loss program prior to completion, while the remaining 18 (50.6 ± 12.1 years old, BMI 33.5 ± 6.2 kg/m^2^) were analyzed ([Figure 1](#F0001){ref-type="fig"}). The remaining subjects participated in supervised exercise therapy twice a month and performed home exercise therapy. Exercise time (walking) three times a week at home was 105.6 ± 55.5 min/week for NTG and 102.2 ± 44.4 min/week for RTG (p \<0.876). The retention rate (Number of program finishers/program participants) for the 6-month weight-loss program was 47% for NTG and 75% for RTG (p \<0.244). Additional RT programs were conducted 2--4 times a day, more than 5 days a week. The RT program achievement rate (RT program achievement rate (days)/prescribed number of programs (days)) was 89.0 ± 15.0%.Figure 1Flow chart of parallel randomized controlled trial between groups. Subjects were randomized into the normal treatment group (NTG) and the RT additional treatment group (RTG).

Changes in Body Composition, Physical Fitness, and Blood Parameters {#S0004-S2002}
-------------------------------------------------------------------

The body weight of NTG and RTG participants was significantly reduced by 6% (p=0.015) and 7% (p=0.011), respectively. VFA decreased by 15.4% (p=0.083) in NTG and 13.4% (p=0.058) in RTG. NTG SFA was significantly reduced by 11.0% (p=0.003) and RTG was reduced by 13.5% (p=0.030). The skeletal muscle mass of the extremities did not differ between groups (p=0.515). The leg strength weight ratio decreased 9.8% for NTG (p=0.515) and increased 2.7% for RTG (p=0.086), but the difference was not significant. As a result of a food analysis by a nutritionist at the time of the first medical examination and at the time of medical examination after 6 months of intervention, the NTG showed that the calories intake was 14.5% (p=0.096), and 53.8% (p=0.120), respectively, and that the total calorie intake was decreased by 20.6% (p=0.094); while the RTG decreased staple food intake calorie by 10.7% (p=0.368), snack intake calorie 29.1% (p=0.198), and total calorie intake by 14.0% (p=0.278). Although a decreasing trend was seen in both groups, it was not significant. PeakVO~2~ of NTG increased by 4.7% (p=0.375) and that of RTG increased by 7.1% (p=0.138), but it was not significant. Each group showed similar weight loss, but there were no significant differences between groups in terms of body composition, exercise capacity, and blood parameters ([Table 5](#T0005){ref-type="table"}).Table 5Changes of Parameters from Baseline to 6-Month Following Weight Reduction Intervention in All ParticipantsVariableNTG (n=9)*p* valueRTG (n=9)*p* valueBaseline ComparisonBeforeAfterBeforeAfter*p* valueAge, years50.7±12.650.6±11.50.724**Body composition** Body weight (kg)83.5±16.578.4±15.5^a^0.01579.9±14.774.3±13.5^a^0.0110.638 Body mass index (kg/m^2^)34.7±6.832.7±6.7^a^0.01632.2±5.529.9±5.0^a^0.0120.417 Body fat(%)46.6±4.444.0±5.4 b0.00944.6±2.842.1±3.80.0540.235 Visceral fat area (cm^2^)170.4±63.1144.2±66.00.083182.3±70.9157.8±87.10.0580.894 Subcutaneous fat area (cm^2^)489.9±146.53^a^435.5±159.4^b^0.003364.7±109.7315.6±89.3^a^0.0300.043 Lean body mass (kg)45.8 (39.1, 48.1)45.1 (38.3, 48.2)0.67840.8 (38.4, 52.6)40.0 (38.1, 49.4)^a^0.0210.825 Limb skeletal muscle mass (kg)18.6 (14.7, 19.7)16.3 (15.0, 18.3)0.51515.8 (15.6, 19.2)15.8 (15.0, 19.6)0.5150.566**Diet data** Calorie intake (kcal)1931.7±645.51650.1±494.30.0961973.3±499.41761.1±241.60.3680.880 Snack calorie intake(kcal)351.7±338.7162.2±96.80.120419.4±228.4296.7±220.20.1980.625 Total calorie intake (kcal)2283.3±900.41812.2±551.90.0942392.8±694.22057.8±319.90.2780.776**Exercise capacity** Leg strength weight ratio (kg/kg)1.49 (1.15, 1.64)1.38 (1.10, 1.74)0.5151.47 (1.30, 1.52)1.51 (1.42, 1.67)0.0860.965 AT (mL/kg/min)11.2 (10.1, 14.0)13.1 (10.7, 13.7)0.49811.9 (11.6, 14.1)15.7 (11.3 16.1)^a^0.0500.314 Peak VO~2~ (mL/kg/min)18.8±3.619.7±5.00.37521.2±5.322.7±4.70.1380.307**Blood parameters** TG (mg/dL)85 (74, 157)80.0 (47, 134)0.374151 (82.5, 169.5)100(65.0, 136.0)0.0860.480 HDL-C (mg/dL)50.2±13.760.3±18.1^b^0.00447.1±9.458.3±11.9^b^0.0020.583 LDL-C (mg/dL)129.2±34.1129.3±22.00.984103.6±27.2114.7±30.30.2660.097 GLU (mg/dL)98.8±8.092.7±8.8^a^0.03599.6±12.397.2±10.90.1110.876 IRI(μIU/mL)13.7±7.814.2±8.70.78411.7±10.010.0±6.70.1360.608 HOMA-IR(×10^-6^mol×IU×L^-2^)3.4±2.13.3±2.10.8462.9±2.12.4±1.80.0890.594 HbA1c (%)5.7±0.25.6±0.2^a^0.0386.5±1.56.0±1.00.2110.165[^5]

Differences in DNA Methylation Between Patient Groups {#S0004-S2003}
-----------------------------------------------------

Comparing median methylation rates, NTG showed that CpG1 (p=0.011), CpG4 (p=0.050), CpG5 (p=0.021), CpG7 (p=0.017), and total value of CpG (p=0.011), which was a decline. In contrast, RTG had an increased CpG3 (p=0.038). Next, in comparison to the methylation change rate calculated from the average value of the data before and after the intervention, NTG showed a decrease in the CpG1 methylation change rate (p=0.004) and the total value of CpG (p=0.019). The rate of change in methylation of RTG was significantly increased only in CpG3 (p=0.038). The mean values consider all the data, so the rate of change was calculated from the mean values before and after the intervention. As a result, the significant differences between the groups were the values of %CpG1, %CpG3, and %total value of CpG ([Table 2](#T0002){ref-type="table"}). As a factor showing a significant correlation with this methylation change rate, in NTG, a negative correlation was observed between %CpG1 and %Body fat (r=−0.683, p=0.042). RTG showed a positive correlation between %CpG1 and %Body fat (r=0.300, p=0.047) and %total calorie intake (r=0.967, p=0.000). Only RTG, %CpG3 was found to have a negative correlation with %VFA (r=−0.817, p=0.007) and %LDL-C (r=−0.867, p=0.002), and %AT (r=0.783, p=0.013) and a positive correlation was recognized. Only RTG showed a positive correlation between %total value of CpG and %PeakVO~2~ (r=0.750, p=0.020) ([Table 3](#T0003){ref-type="table"}). In stepwise multiple regression analysis, the methylation change rate (%CpG) that was significant before and after the intervention between groups was used as the dependent variable, and the factors that were significantly correlated with each methylation change rate were used as the independent variables. As a result the independent factors that determine %CpG1 was the presence or absence of resistance training (β=0.592, p=0.001) and %total calories consumed (β=0.480, p=0.006).%CpG3 was the presence or absence of resistance training (β=0.517, p=0.012) and %VFA (β=−0.568, p=0.007). %Total value of CpG was the presence or absence of resistance training (β=0.401,p=0.028) and %PeakVO~2~ (β=0.620,p=0.002) ([Table 4](#T0004){ref-type="table"}).

Discussion {#S0005}
==========

This study quantified *FTO* whole blood DNA methylation and investigated its relationship to body composition, exercise capacity, and blood parameters with a 6-month weight-loss program intervention. We extracted *FTO* DNA from whole blood at the time of blood collection and analyzed the 5ʹUTR of the non-promoter genomic region. As a result, the methylation rate of NTG CpG1, CpG4, CpG5 and CpG7 was decreased, and the methylation rate of RTG CpG3 was increased. We predicted that decreases in body weight and fat mass increased DNA methylation rates in both groups. However, the decrease in the methylation rate of NTG showed the opposite result as expected. Luo et al reported that the CpG density in the 5ʹUTR region was high, but the DNA methylation level was relatively low and was negatively correlated with gene expression.[@CIT0036] It has also been reported that hypomethylation of the *FTO* non-promoter region is an early marker of T2D.[@CIT0026] Church et al found that reduced methylation (hypomethylation) induces overeating, fat accumulation, and obesity. It has been reported that increased methylation suppresses gene expression and decreased methylation promotes gene expression.[@CIT0015]--[@CIT0020] The methylation of 4 cytosine guanine dinucleotide site (CpG sites) of NTG was decreased and the methylation of 1 CpG site of RTG was increased.

Next, the percent change in methylation calculated from the mean before and after the intervention to assess subjects' methylation profile was significantly reduced of %CpG1 and %total value of CpG in NTG. RTG significantly increased %CpG3. We extracted the variables that showed a significant correlation with these change rates. A stepwise multiple regression analysis, adjusted for age and presence or absence of resistance training, showed that an independent factor defining RTG %CpG1 was positively correlated with %total calories and resistance training.

This suggests that resistance training may increase the rate of change in CpG methylation due to weight loss, even when eating well; in other words, it may suppress *FTO*. The independent factors that define %CpG3 of RTG were %VFA and the presence or absence of resistance training. The negative association with %VFA was shown only in RTG, which suggests that the decrease in visceral fat area change rate and the increase in CpG3 methylation change rate associated with weight loss may be related to *FTO* suppression. It has been reported that VFA is more sensitive to lipolysis and has higher metabolic activity than SFA.[@CIT0037] However, the absolute value of VFA showed a decreasing trend, but no significant difference was observed. The reason for the insignificant changes was due to low exercise intensity and duration. The independent factors that determine the %Total value of CpG of RTG were %PeakVO~2~ and the presence or absence of resistance training. The positive association with PeakVO~2~ was shown only in RTG since the increase in PeakVO~2~ change rate with weight loss was associated with the increase in %Total value of CpG change rate. [Tables 3](#T0003){ref-type="table"} and [4](#T0004){ref-type="table"} show that the PeakVO~2~ had an increasing tendency, but no significant change was observed. The reason why the absolute value of peakVO~2~ did not increase was that no significant increase was obtained due to low exercise intensity and duration. However, AT showed a significant increase. This indicates that even if the dose is low, continuing resistance training for 6-month may contribute to improving aerobic capacity. As described above, similar weight reduction effects were observed in the body composition parameters of each group. The significant rate of change in RTG DNA level was associated with an independent factor.

In this study, the changes in the methylation rate before and after the intervention were subtle. Rönn et al reported that the changes in DNA methylation observed in response to exercise intervention may be modest, yet the affected sites may combine to contribute to the physiological response. Furthermore, significant changes in methylation are not necessarily sites of high methylation changes. Even in regions with low methylation changes (non-promoter region) such as 5ʹuntranslated region (5ʹUTR) and 3ʹuntranslated region (3ʹUTR), significant changes can occur within 0.2--10.9%.[@CIT0023],[@CIT0035] Aronica et al meta-analysis reported that the magnitude of DNA methylation changes identified was less than 5%, the smallest change reproducibly detectable on most platforms.[@CIT0024] In addition, in a report in which hypomethylation of the *FTO* non-promoter region is an early marker of T2D, a methylation rate of 0.4--7.2% has been reported.[@CIT0019],[@CIT0026],[@CIT0027] Based on these reports, considering the fact that are significant changes in obesity-related methylation due to differences in exercise interventions, such as this time, body composition, even if there is a certain weight-reducing, effect the parameters and blood properties, if methylation is significantly decreased, it may indicate the direction of promoting *FTO* gene expression, that is, the possibility of future T2D.

Many studies of CpG sites that show altered methylation rates indicate that these sites are essential for gene regulation. However, the function of the CpG site remains unknown, and little is known regarding the rate of change in CpG methylation in mammals and the environmental factors that influence changes in DNA methylation patterns.[@CIT0038] Regulation of gene expression is an important factor in the associated individual differences. The mechanism by which epigenetic alterations cause obesity at specific loci is unknown.[@CIT0039] Aronica et al meta-analysis reported that altered methylation at the identified CpG sites was the result rather than the cause of obesity, and altered BMI was responsible for the altered methylation. Long-term observations that obesity precedes changes in DNA methylation report that DNA methylation levels are likely to mediate obesity and health effects.[@CIT0024] However, it is currently unknown what phase of BMI changes CpG and in which region, and how methylation kinetics changes when obesity is eliminated. It is important to manage obesity to prevent or eliminate obesity-based diseases. To that end, lifestyle interventions have been reported to be effective, delay or prevent the onset of complications, and significantly reduce the burden on individuals with diabetes and public health.[@CIT0040] Irwin et al encourage moderate exercise as a way to reduce obesity and prevent chronic illness.[@CIT0041] This exercise program set low intensity resistance training that can be practiced at home for a relatively long period of time. To obtain a significant weight reduction effect on the body composition, exercise capacity, and blood parameters, it is an issue to continue the exercise with moderate intensity.

This study has some limitations. First, the study group contained only 18 participants, which may be too small to detect differences in DNA methylation and characterize participants. We believe that stratified randomization is necessary to minimize potential confounders and random variations that affect reproducibility. Moreover, it is possible that this methylation kinetics is not related to a clear biological mechanism. Only NTG showed a significant difference in SFA because participants had severe subcutaneous fat obesity at baseline. Second, the level of activities of daily living could not be quantified. Both groups achieved similar weight loss, but daily activities outside the program may have affected body composition and exercise tolerance. In the future, monitoring physical activity in daily life should be considered. Third, in this study, DNA analysis was performed using whole blood as an easily accessible method at the time of blood sampling in consideration of ethical issues and invasiveness. However, whole blood also has a high level of cell-type heterogeneity, and in view of tissue specificity, it has been pointed out that the blood methylation profile may not necessarily reflect the epigenetic status of other tissues.[@CIT0024],[@CIT0028] In the future, samples will need to be examined both in blood and tissue and other obesity-related candidate gene analyses. Additionally, areas and methods of analysis and intervention programs should be revaluated.

Conclusions {#S0006}
===========

The methylation rate of NTG was significantly decreased at four CpG sites, and RTG was significantly increased at one CpG site. Decreased methylation promotes gene expression and increased methylation suppresses gene expression. In the methylation change rate, %CpG3 of RTG was significantly increased. In addition, %CpG3 was negatively associated with %VFA. This indicates that the rate of change in visceral fat area with weight loss may increase the rate of change in CpG3 methylation. Therefore, the reduction in visceral fat area, caused by the weight-loss program that included resistance training, may be associated with increased methylation of CpG3 in the non-promoter region of whole blood *FTO*. However, this study is merely a proof of concept, and further replication studies with larger sample sizes are warranted.
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[^1]: **Note:** Primer sequences and CpG locations for the loci.

    **Abbreviations:** *FTO*, fat mass and obesity-related genes; TSS, transcriptional termination site.

[^2]: **Notes:** Values are shown as median (25%, 75% quartile). ^a^p \< 0.05, ^b^p \< 0.01. Comparison before and after intervention for each group using Wilcoxon signed-rank test. Comparison of baseline interventions in each group using Mann--Whitney *U*-test and between-group comparisons of methylation change rates. NTG, normal treatment group; RTG, resistance training additional treatment group; Change rate, methylation change rate. Change rate was calculated from the data average before and after the intervention (measured value after intervention-measured value before intervention)/measured value before intervention x 100 *FTO*, fat mass and obesity-associated; 5ʹ UTR region, five prime untranslated region.

[^3]: **Notes:** ^a^p \< 0.05, ^b^p \< 0.01. *ρ*, Spearman's rank correlation coefficient.

[^4]: **Notes:** ^a^p \< 0.05, ^b^p \< 0.01. β, standardized partial regression coefficient. R^2^, adjusted coefficient of determination.

[^5]: **Notes:** Values are shown as mean ± standard deviation or median (25%, 75% quartile). ^a^p \< 0.05, ^b^p \< 0.01. Comparison before and after intervention of each group using paired *t*-test or Wilcoxon Sign Rank test. Baseline-intervention comparisons for each group using unpaired *t*-test or Mann--Whitney *U*-test.

    **Abbreviations:** NTG, normal treatment group; RTG, resistance training additional treatment group. Groups: NTG vs RTG. AT, anerobic threshold; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; GLU, glucose; IRI, immunoreactive insulin. HOMA-IR, homeostasis model assessment-insulin resistance; HbA1c, hemoglobin A1c.
